TRuST : Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer

Systemic therapy | Blood / Myeloma / Lymphoma,Lung,Sarcoma,Urinary systemB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Kidney,Lung,Lymphoma,Mesothelioma,Sarcoma,Soft Tissue Sarcoma,Synovial Sarcoma

Trial Overview Read MoreRead more

This study will provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in a previous study.

This trial is treating multiple types of cancer including Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Synovial Sarcoma, Epitheliod Sarcoma or Mesothelioma.

This is a systemic therapy rollover.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

Commercial Sponsor

Epizyme, Inc.


Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Ms Anita Cummins
03 9594 4044

PCCTU (Parkville Cancer Clinical Trials Unit) *
Ms Marian Lieschke
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.